Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
grade D 7.52 11.08% 0.75
ALIM closed up 11.08 percent on Friday, December 6, 2019, on 1.27 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Up Up
See historical ALIM trend table...

Date Alert Name Type % Chg
180 Bullish Setup Bullish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
NR7 Range Contraction 11.08%
Upper Bollinger Band Walk Strength 11.08%
Wide Bands Range Expansion 11.08%
Overbought Stochastic Strength 11.08%

Older signals for ALIM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Medicine Chemistry Biopharmaceutical Diseases Organ Systems Disease Diabetes Age Related Macular Degeneration Blindness Diabetic Retinopathy Fluid Dynamics Glucocorticoids Macular Edema Diabetic Macular Edema Retina Pregnanes Alimera Sciences Diketones Retinal Vein Occlusion

Is ALIM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 18.15
52 Week Low 2.9595
Average Volume 65,197
200-Day Moving Average 10.74
50-Day Moving Average 5.50
20-Day Moving Average 5.23
10-Day Moving Average 6.08
Average True Range 0.73
ADX 51.46
+DI 44.12
-DI 4.33
Chandelier Exit (Long, 3 ATRs ) 5.66
Chandelier Exit (Short, 3 ATRs ) 5.15
Upper Bollinger Band 7.64
Lower Bollinger Band 2.81
Percent B (%b) 0.97
BandWidth 92.49
MACD Line 0.52
MACD Signal Line 0.19
MACD Histogram 0.3293
Fundamentals Value
Market Cap 519.24 Million
Num Shares 69 Million
EPS -0.39
Price-to-Earnings (P/E) Ratio -19.28
Price-to-Sales 2.38
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.89
Resistance 3 (R3) 8.79 8.23 8.66
Resistance 2 (R2) 8.23 7.89 8.28 8.58
Resistance 1 (R1) 7.88 7.67 8.06 7.98 8.51
Pivot Point 7.32 7.32 7.41 7.37 7.32
Support 1 (S1) 6.97 6.98 7.15 7.07 6.53
Support 2 (S2) 6.41 6.76 6.46 6.46
Support 3 (S3) 6.06 6.41 6.38
Support 4 (S4) 6.16